NEW YORK, Feb. 7 (GenomeWeb News) - Decision Biomarkers closed a $7.6-million Series A financing round, the company said Friday.
Oxford Bioscience Partners led the round. Investors included Rock Maple Ventures, Fletcher Spaght Venture Partners, and a group of individual investors led by Coco Montagu.
The company said it would use the capital to "fast-track" its technology for reducing "overall drug development costs."
"This funding will be used to complete the product launch and achieve early sales," said CEO Roger Dowd in a statement.
The Waltham, Mass.-based company makes a fully automated platform that enables researchers to test up to 40 biomarkers at one time.